Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
Active Biotech |
Chelsea Therapeutics International Ltd.(CHTP) |
Deal to develop Active Biotech's I-3D portfolio of DHODH-inhibiting compounds for autoimmune diseases and transplant rejection |
They will jointly fund and develop the dihydroorotate dehydrogenase compounds; Chelsea gets rights in North and South America; each would pay the other royalties on sales; Active Biotech also could earn milestone payments in the deal (5/9) |
Alnylamz |
Bioneer Inc.* (South Korea) |
Bioneer got nonexclusive rights to provide RNAi research products under Alnylam's siRNA patents |
Bioneer will use rights to the Kreutzer- Limmer patent family in the area of oligo- nucleotide production; terms of the deal were not disclosed (5/24) |
Angiotech |
Genzyme Corp. (GENZ) |
Collaboration to develop and market therapies for cancer patients undergoing surgical removal of tumors |
Each company will contribute technology and expertise to the effort; costs and any profits will be shared equally; Genzyme has primary responsibility for development and commercialization (5/9) |
Argenta |
PainCeptor Inc.* (Canada) |
Argenta will use its technologies to help accelerate PainCeptor's acid-sensing ion channel development program |
The program is focused on therapeutics for pain; terms were not disclosed, but they do provide options to expand the relationship (5/2) |
Athersys Inc.* |
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
Deal to develop cell-based products for treating cardiovascular diseases; the initial focus is on Athersys' MultiStem adult stem cell-derived product |
Angiotech made an investment in Athersys; Athersys also is entitled to milestone payments; they will share costs and any resulting profits (5/15) |
BioImage |
TopoTarget |
TopoTarget exercised its option to purchase all ownership of the cancer drug TOP216 |
The deal covers a class of small molecules that inhibit the mTOR signaling pathway; terms of the deal were not disclosed (5/22) |
Bioniche Life |
Bioniche Teoranta* (Ireland) |
Bioniche Teoranta acquired the sodium hyaluronate product Cystistat from BLSI |
Bioniche Teoranta is paying about $9M; it is part of the Bioniche Pharma Group, which BLSI sold earlier in 2006 to an investor group (5/3) |
BioStratum |
NephroGenex Inc.* |
NephroGenex acquired rights to Pyridorin and second-generation compounds for treating diabetic nephropathy |
Pyridorin has completed two Phase II trials in that indication; terms of the deal were not disclosed (5/10) |
Brookwood |
Genzyme Pharmaceuticals (unit of Genzyme Corp.;GENZ) |
They entered a broad collaboration to develop drug delivery solutions, with an initial focus on peptide delivery |
They plan to use their synergistic capabil- ities in the program; terms of the deal were not disclosed (5/2) |
Cellgate |
Isotechnika Inc. (Canada; TSE:ISA) |
Option agreement to apply Cellgate's transporter technology for the topical delivery of Isotechnika's ISA24 |
The effort targets treatment of psoriasis; Cellgate is getting $0.5M and will perform feasibility studies; Isotechnika then could license the technology (4/25) |
Cetek Corp.* |
Lexicon Genetics Inc. (LEXG) |
Cetek will provide a library derived from natural products for use by Lexicon in drug discovery |
Cetek also will work to identify compounds with activity against targets screened by Lexicon, which could license resulting com- pounds; terms were not disclosed (4/26) |
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
Genentech extended funding to support Curis research services through December, with an option to extend funding until June 2007 |
Funds will support the companies' ongoing research in the Hedgehog antagonist program and development of xenograft models for use in other Genentech programs (5/9) |
Crucell NV |
Upstate USA Inc. (subsidiary of Serologicals Corp.; SERO) |
Upstate got nonexclusive rights to use the PER.C6 cell line to propagate adenovirus containing siRNA |
The siRNA will be supplied to Upstate via a separate agreement with Galapagos BV, Crucell's PER.C6 licensee in the field of functional genomics; Upstate will pay a license fee, annual maintenance fees and a running royalty (5/16) |
Cytogen |
Progenics Pharmaceuticals Inc. (PGNX) |
Progenics purchased Cytogen's 50% interest in their joint venture to develop PSMA- based cancer immunotherapies |
Cytogen received $13.2M up front and could get up to $52M in milestone payments, as well as royalties on resulting sales (4/24) |
Dyax Corp. |
ICOS Corp. (ICOS) |
ICOS got a nonexclusive license to phage display libraries for use in antibody discovery and development |
Dyax gets technology license fees, as well as potential milestone payments and royalties on resulting sales (5/22) |
Elusys |
MedImmune Inc. (MEDI) |
MedImmune got rights to infectious disease targets from Elusys |
Elusys gets an up-front payment and equity investment in the deal, as well as potential milestone and royalty payments (4/20) |
EpiStem Ltd.* |
Callisto Pharmaceutials Inc. (AMEX:KAL) |
EpiStem will provide Callisto preclinical efficacy testing in the area of inflammatory bowel disease |
EpiStem will profile Callisto's Guanilib and other agents; terms of the deal were not disclosed (5/10) |
Galapagos |
Upstate USA Inc. (subsidiary of Serologicals Corp.; SERO) |
They entered a marketing deal for Galapagos' adenovirus products worldwide, excluding Japan |
Upstate will promote the reagents as research tools in drug discovery; Galapagos will receive double-digit royalties on resulting sales (5/17) |
Gilead |
Diatos SA* (France) |
Diatos acquired worldwide rights to DaunoXome, a liposomal formulation of daunorubicin sold in more than 20 countries |
Gilead gets up-front and milestone payments of up to $4.7M, as well as royalties on sales; the product is indicated for AIDS/ HIV-related Kaposi's sarcoma and is being evaluated in other cancers (5/11) |
Illumina Inc. |
DeCode Genetics Inc. (Iceland; DCGN) |
Collaboration to develop and market DNA-based diagnostic tests in several disease areas |
Illumina will use its genotyping platform to develop tests for gene variants identified by DeCode; costs and any profits will be shared (5/15) |
ImmunoGen |
Genentech Inc. (NYSE:DNA) |
Collaboration to create a commercial manufacturing process for Genentech's trastuzumab-DM1 TAP compound |
They also amended 2000 agreement, giving Genentech exclusive rights to use ImmunoGen's TAP technology with antibodies to HER2, increasing ImmunoGen's milestone and royalty potential (5/4) |
Invitrogen |
Locus Pharmaceuticals Inc.* |
Invitrogen will provide kinase screening services to Locus through its SelectScreen platform |
Services will support Locus discovery programs, principally in cancer and inflammation; terms of the deal were not disclosed (5/16) |
Novogen Ltd. |
Marshall Edwards Inc. (MSHL) |
Marshall Edwards acquired rights to the oncology compounds NV-196 and NV-143; it has first rights to license Novogen cancer compounds |
Novogen gets $1M up front, potential mile- stone payments and royalties of 5% on any resulting sales; Marshall Edwards is majority owned by Novogen (5/15) |
Oxford Gene |
Eurogentec |
Eurogentec licensed rights to patents covering oligo-nucleotide microarrays |
The licenses are to OGT's Southern array patents; terms were not disclosed (4/26) |
Oxford |
Medarex Inc. (MEDX) |
Collaboration to discover and develop antibody therapeutics for treating cancers, including colorectal cancer |
They will use OGS' discovery capabilities and Medarex's antibody expertise in the effort; cost and any profits will be shared equally (5/10) |
Oy Jurilab |
Nanogen Inc. (NGEN) |
Collaboration to identify and validate prognostic markers for Type II diabetes |
Nanogen gains access to markers identified by Jurilab; Nanogen intends to develop diagnostic tests, and they plan to license out therapeutic rights (5/15) |
Pathogenics |
Acuity Pharmaceuticals Inc.* |
Acuity got worldwide rights to N-chlorotaurine for treating ophthalmic infections and other diseases |
Pathogenics retains rights outside ophthalmology indications; it gets an up-front fee, annual license payments and potential milestone and royalty payments (4/19)# |
Pharmacopeia |
Cephalon Inc. (CEPH) |
Collaboration to identify active molecules in various therapeutic areas and take them to clinical proof of concept |
Pharmacopeia gets a $15M up-front access fee; Cephalon has primary development and commercialization responsibility, with Pharmacopeia retaining a development option; the developing company would pay the other milestone and royalty payments on resulting products (5/23) |
PharmaSeed |
AlphaRx Inc. (Canada; OTC BB: ALRX) |
Collaboration to develop drugs for treating central nervous system disorders |
PharmaSeed will evaluate the AlphaRx compounds in stroke and multiple sclerosis models; they may create a joint venture for commercialization of resulting compounds (5/11) |
Qualigen Inc.* |
Gen-Probe Inc. (GPRO) |
Gen-Probe exercised its option to develop a nucleic acid testing platform based on Qualigen's |
Gen-Probe purchased $7M in Qualigen preferred stock, convertible into about 19.5% of Qualigen (4/20) |
Resdevco |
Safetek International Inc. (OTC BB:SFIN) |
Deal under which Safetek could acquire rights to all of Resdevco's technology related to antioxidant compounds |
Resdevco would get yearly payments and royalties on resulting sales, if Safetek decides to go through with the deal (4/24) |
Rosetta |
U.S. Genomics Inc.* |
Deal to discover and develop a microRNA-based, non- invasive early detection test for lung cancer |
The effort combines U.S. Genomics' Trilogy 2020 platform and Direct miRNA assay with Rosetta's microRNAs; terms were not disclosed (5/24) |
Sphergen |
Inovio Biomedical Corp. (AMEX:INO) |
Inovio licensed rights to several patent families relating to the use of electroporation technology |
The deal broadens Inovio's position in using electroporation technology for drug delivery; terms were not disclosed (5/15) |
Synergia |
Chelsea Therapeutics International Ltd. (CHTP) |
Chelsea is acquiring all rights to L-Threo DOPS |
The synthetic amino acid is marketed in Japan for treating neurogenic orthostatic hypotension; terms of the deal were not disclosed (5/8) |
Taligen |
XOMA Ltd. (XOMA) |
Deal for the development and manufacturing of an antibody fragment from Taligen for treating inflammatory diseases |
XOMA will manufacture the product for pre- clinical studies; it intends to negotiate a longer-term definitive agreement later in 2006 (5/17) |
TcLand SA* |
Debiopharm SA* (Switzerland) |
Debiopharm got an option on rights to the fusion protein sc28AT, a CD28 antagonist in preclinical development for blocking graft rejection |
Debiopharm will make an equity investment in TcLand and fund further R&D on the product; TcLand also is entitled to milestone and royalty payments (5/22) |
Uluru Inc. |
BioProgress plc (UK; BPRG) |
Joint development deal, initially focused on an anti-emetic product for the relief of nausea |
They will use BioProgress' film technology and Uluru's Oradisc delivery technology in the program; terms of the deal were not disclosed (5/4) |
Viragen Inc. |
AFG BioSolutions Inc.* |
AFG will study Viragen's Multiferon as an antiviral agent against a variety of biological threats |
AFG will conduct in vivo research on the interferon agent; its research primarily is funded by biodefense contracts and government grants; terms of the deal were not disclosed (5/9) |
Xgene Corp.* |
Advanced Cell Technology Inc. (OTC BB:ACTC) |
Deal under which Xgene will assess the performance of ACT's dermatology technologies |
The goal is to test the functionality of embryonic skin cells in regenerating skin for various applications; terms were not disclosed (4/27) |
XOMA Ltd. |
AVEO Pharmaceuticals Inc.* |
XOMA will humanize AV-299, AVEO's anti-hepatocyte growth factor monoclonal antibody |
XOMA gets an up-front license fee and potential milestone and royalty payments; AVEO retains all rights to AV-299 (4/27) |
ZaBeCor |
Acuity Pharmaceuticals Inc.* |
Acuity optioned rights to ophthalmic applications of an anti-inflammatory siRNA agent |
ZaBeCor is developing the siRNA agent for pulmonary use under the trade name Excellair; terms of the deal were not disclosed (4/28) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.